D'Orazio & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $410K | Buy |
+6,768
| New | +$395K | 0.05% | 143 |
|
|
2025
Q2 | – | Sell |
-3,837
| Closed | -$234K | – | 281 |
|
|
2025
Q1 | $234K | Buy |
3,837
+159
| +4% | +$9.27K | 0.04% | 206 |
|
|
2024
Q4 | $208K | Buy |
+3,678
| New | +$206K | 0.03% | 217 |
|
|
2023
Q4 | – | Sell |
-5,955
| Closed | -$346K | – | 191 |
|
|
2023
Q3 | $346K | Sell |
5,955
-1,113
| -16% | -$68.2K | 0.08% | 86 |
|
|
2023
Q2 | $452K | Buy |
7,068
+2,039
| +41% | +$137K | 0.11% | 71 |
|
|
2023
Q1 | $349K | Sell |
5,029
-3,835
| -43% | -$270K | 0.09% | 81 |
|
|
2022
Q4 | $638K | Buy |
8,864
+1,316
| +17% | +$99.2K | 0.15% | 54 |
|
|
2022
Q3 | $537K | Buy |
7,548
+1,336
| +22% | +$96.9K | 0.16% | 51 |
|
|
2022
Q2 | $478K | Buy |
6,212
+648
| +12% | +$49.4K | 0.13% | 55 |
|
|
2022
Q1 | $406K | Buy |
5,564
+1,105
| +25% | +$74.2K | 0.1% | 62 |
|
|
2021
Q4 | $278K | Buy |
4,459
+119
| +3% | +$6.98K | 0.06% | 80 |
|
|
2021
Q3 | $257K | Buy |
4,340
+346
| +9% | +$22.8K | 0.06% | 75 |
|
|
2021
Q2 | $267K | Buy |
3,994
+2,336
| +141% | +$152K | 0.07% | 69 |
|
|
2021
Q1 | $105K | Buy |
1,658
+645
| +64% | +$40.1K | 0.03% | 113 |
|
|
2020
Q4 | $63K | Buy |
1,013
+24
| +2% | +$1.48K | 0.02% | 136 |
|
|
2020
Q3 | $60K | Buy |
989
+2
| +0.2% | +$120 | 0.02% | 124 |
|
|
2020
Q2 | $58K | Sell |
987
-49
| -5% | -$2.93K | 0.03% | 124 |
|
|
2020
Q1 | $58K | Buy |
1,036
+2
| +0.2% | +$122 | 0.03% | 116 |
|
|
2019
Q4 | $66K | Buy |
1,034
+2
| +0.2% | +$115 | 0.02% | 126 |
|
|
2019
Q3 | $52K | Buy |
1,032
+52
| +5% | +$2.44K | 0.02% | 141 |
|
|
2019
Q2 | $44K | Sell |
980
-25
| -2% | -$1.16K | 0.01% | 152 |
|
|
2019
Q1 | $48K | Buy |
1,005
+28
| +3% | +$1.4K | 0.01% | 147 |
|
|
2018
Q4 | $51K | Buy |
977
+2
| +0.2% | +$107 | 0.02% | 125 |
|
|
2018
Q3 | $61K | Buy |
975
+214
| +28% | +$12.7K | 0.02% | 113 |
|
|
2018
Q2 | $42K | Hold |
761
| – | – | 0.02% | 133 |
|
|
2018
Q1 | $48K | Sell |
761
-157
| -17% | -$10.1K | 0.02% | 121 |
|
|
2017
Q4 | $56K | Buy |
918
+120
| +15% | +$7.51K | 0.02% | 119 |
|
|
2017
Q3 | $51K | Hold |
798
| – | – | 0.02% | 111 |
|
|
2017
Q2 | $44K | Buy |
798
+37
| +5% | +$2.01K | 0.02% | 132 |
|
|
2017
Q1 | $41K | Hold |
761
| – | – | 0.02% | 130 |
|
|
2016
Q4 | $44K | Hold |
761
| – | – | 0.02% | 120 |
|
|
2016
Q3 | $41K | Hold |
761
| – | – | 0.02% | 122 |
|
|
2016
Q2 | $56K | Hold |
761
| – | – | 0.02% | 102 |
|
|
2016
Q1 | $48K | Buy |
761
+261
| +52% | +$16.5K | 0.02% | 117 |
|
|
2015
Q4 | $34K | Sell |
500
-73
| -13% | -$4.82K | 0.02% | 115 |
|
|
2015
Q3 | $37K | Buy |
573
+73
| +15% | +$4.63K | 0.02% | 113 |
|
|
2015
Q2 | $34K | Hold |
500
| – | – | 0.02% | 120 |
|
|
2015
Q1 | $32K | Hold |
500
| – | – | 0.03% | 128 |
|
|
2014
Q4 | $30K | Hold |
500
| – | – | 0.02% | 117 |
|
|
2014
Q3 | $26K | Hold |
500
| – | – | 0.02% | 128 |
|
|
2014
Q2 | $24K | Hold |
500
| – | – | 0.02% | 135 |
|
|
2014
Q1 | $26K | Hold |
500
| – | – | 0.02% | 125 |
|
|
2013
Q4 | $27K | Buy |
+500
| New | +$25.5K | 0.02% | 109 |
|
Other funds holding BMY
VCM
VPM
D'Orazio & Associates's BMY Position: Q1 2026 in Review
D'Orazio & Associates opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 6,768 shares worth $410K. The stake represents 0.05% of the portfolio and ranks #143 among its holdings. This is a return to the name: D'Orazio & Associates previously reported a position in BMY as recently as Q1 2025.
D'Orazio & Associates first reported a position in BMY in Q4 2013 and has held it in 43 quarters since. The position peaked at $638K in Q4 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- D'Orazio & Associates held 6,768 shares of Bristol-Myers Squibb worth $410K as of Q1 2026.
- Bristol-Myers Squibb was a new D'Orazio & Associates position in Q1 2026.
- Bristol-Myers Squibb made up 0.05% of D'Orazio & Associates's portfolio in Q1 2026, its #143 holding.
- D'Orazio & Associates first reported a position in Bristol-Myers Squibb in Q4 2013 and has held it in 43 quarters since.
- D'Orazio & Associates's Bristol-Myers Squibb position peaked at $638K in Q4 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on D'Orazio & Associates's 13F filing for Q1 2026, filed 7 May 2026.